In this issue:
Increased risk of infections in SMM vs MGUS
Real-world risk of infection in patients undergoing front-line daratumumab-based therapy
Talquetamab treatment does not impair humoral immunity
TLG improves prognostication in patients with extramedullary disease
Factors impacting renal recovery in myeloma patients with CAN-related acute renal failure
Brilliant finds no significant cognitive decline after transplant
Linvoseltamab bests teclistamab for RRMM in indirect comparison
Risk of second primary malignancy with lenalidomide may have been inflated
Transcriptional plus genetic profiling virtually eliminates cases of FHR disease
Promising efficacy for talquetamab + daratumumab for RRMM
Please login below to download this issue (PDF)